The MIND diet was associated with slower cognitive decline in both Black and white older adults, but relationships appeared ...
The AAV-GAD bridging study met the primary endpoint of safety and tolerability, and showed early promise in Parkinson’s ...
Alec Stranahan, an analyst from Bank of America Securities, maintained the Buy rating on Meiragtx Holdings (MGTX – Research Report). The ...
The company said the latest positive safety, tolerability, and efficacy data will underpin discussions with regulators in the US, Europe, and Japan.
MeiraGTx Holdings ’ MGTX clinical bridging study of its gene therapy candidate, AAV-GAD, for treating Parkinson’s disease (PD) met its primary study objective of safety and tolerability. The stock ...